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A B S T R A C T 
Several lines of evidence showed that apoptosis rate of cumulus cells in oocytes derived by assisted 
reproductive technologies could be used as an indicator of fertilizing gamete quality.  Aim of the study 
was to investigate the effects of three different ovarian stimulation protocols on the biological and clinical 
outcome in hyporesponder patients. Collected data showed a higher significant rate of DNA fragmentation 
index (DFI) in U group (patients treated with Highly Purified human Menopausal Gonadotrophin) than in 
P group (treated with recombinant human Follicle Stimulating Hormone (r-hFSH) combined with 
recombinant human Luteinizing Hormone (r-hLH)). Both groups R (treated with r-hFSH alone) and P 
showed a significant increase in collected and fertilized oocytes number, embryo quality number. This 
study showed that combined r-hFSH/r-hLH therapy could represent the best pharmacological strategy for 
controlled ovarian stimulation and suggests to use DFI as a biomarker of ovarian function in 
hyporesponder patients. 
© EuroMediterranean Biomedical Journal  2017 
 
1. Introduction 
Ovarian follicle development is a complex process; granulosa and 
cumulus cells could play a pivotal role during the preovulatory phase, 
synchronizing nuclear and cytoplasmic maturation through the complete 
suppression of oocyte transcription until nuclear maturity. Paracrine 
interactions between somatic and germ cells are critical for normal 
follicular development [1]. Somatic cells in ovaries are known to 
participate in regulating oocyte growth and development, meiosis, and 
global transcriptional activity [2]. On the other hand, oocytes promote 
granulosa cell proliferation and differentiation [3]. In the assisted 
reproductive technologies (ARTs) clinical routine, the oocyte selection is 
based on the morphological parameters of the cytoplasm, polar body and 
cumulus cells [4]. However, all the morphological criteria for grading and 
screening of oocytes are subjective and controversial, and are not related 
to the intrinsic competence of the oocyte [5]. Research is designed to 
define objective and non-invasive molecular markers predictive of oocyte  
 
competence. It has been demonstrated that the apoptosis rate of cumulus 
cells in women who achieved pregnancy was considerably lower than in 
women who did not become pregnant. In animal studies, both oocyte 
DNA fragmentation and their apoptosis might account for poor oocyte 
competence and lower fertility [6-7]. Cumulus cell apoptosis rate has been 
evaluated to verify its relationship with pregnancy and implantation rate in 
different studies. With this in mind, cumulus cell apoptosis rate was 
suggested as molecular marker in selecting oocytes with higher 
implantation potentiality [8-10]. 
In our previous study [11], we have demonstrated that r-hLH 
supplementation during ovarian stimulation, significantly reduced 
apoptosis in the cumulus cells, improving oocyte competence, which is 
necessary for adequate fertilization and a consequent embryo 
implantation. 
HP-hMG, r-hFSH and a combination of r-hFSH/r-hLH, are commonly 
used for for controlled ovarian stimulation (COS) in infertile women 
undergoing IVF/ICSI treatments. Several publications have compared the    
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effectiveness of these compounds [12]. Most studies have been performed 
in women undergoing pituitary down-regulation with a GnRH agonist 
long protocol, focusing on the outcome after r-hFSH and HP-hMG 
ovarian stimulation [13]. Two meta-analyses showed that HP-hMG 
ovarian stimulation accounts for an increased live birth rate compared to 
r-hFSH in the GnRH agonist long protocol [14].  
In clinical practice, HP-hMG is the treatment of choice when LH activity 
is required to achieve successful ovarian stimulation; this is due to the LH 
activity present in hCG added to this formulation. 
Several studies have suggested to add LH activity to FSH to stimulate 
ovarian function in IVF/ICSI-embryo transfer to improve clinical 
outcomes [15], but they have not been able to address the role that LH 
administration plays during the follicular phase of a stimulation cycle for 
IVF-ET, under pituitary suppression. When r-hFSH is administered to 
normo-gonadotrophic patients, low levels of endogenous LH can still be 
present, following pituitary down-regulation with GnRH analogues [16]. 
It is known that only 1% of LH receptors need to be occupied to drive 
adequate ovarian steroidogenesis for reproduction [17], but the potential 
benefit of additional exogenous LH supplementation in ARTs is still 
controversial [18]. Different meta-analyses did not demonstrate any 
clinical benefit from r-hLH supplementation [19]. However, in older 
patients undergoing ARTs, the addition of r-hLH seems to be beneficial 
[20].  
The first aim of this study was to determine oocyte competence. We 
further compared the effects of stimulation therapy with r-hFSH, r-
hFSH/r-hLH or HP-hMG (containing hCG as LH-like activity) in patients 
undergoing ICSI. 
 
2. Material and methods 
Study design 
 
This prospective observational study was performed on 61 patients, being 
treated at the “Centro di Biologia della Riproduzione”, Palermo, Italy. 
Patients were included in the observation after signing the Informed 
Consent which included both the agreement for the study participation and 
for the possible use of any discarded cumulus cells for apoptosis rate 
assessment. The patients involved in the study were classified hypo-
responders given that they presented a normal basic level of FSH < 12 
IU/mL and had undergone previous r-hFSH stimulation cycles with more 
than 3.000 IU to have a reasonable clinical outcomes. These patients were 
aged 30-40 years and normal body mass index (BMI = kg/m2<25) (table 
1).  
All patients received a GnRH agonist (Buserelin, Suprefact , Sanofi-
Aventis, Italy, 0.2 mL/d), starting on day 21 of the previous cycle, long 
protocol; 21 patients were stimulated with r-hFSH alone (R group); 18 
patients, were treated with r-hFSH combined with r-hLH (150 IU r-hFSH 
/ 75 IU r-hLH, 2:1 ratio) (P group); and 22 patients were treated with HP-
hMG (U group) (table 2).  
Administration of 150 IU r-hFSH / 75 IU r-hLH (Pergoveris®; Merck 
Serono, Italy) started from day 3 of the cycle in P group. The stimulation 
therapy for R group consisted of a fixed initial dose of r-hFSH (Gonal-F; 
Merck Serono, Italy, 150 IU), while in U group the treatment consisted of 
HP-hMG (Meropur®, Ferring, Italy, 150 IU), starting from day 3 of the 
cycle. Follicular growth was monitored on a daily basis using ultrasound 
and serum estradiol (E2) levels, starting on day 6 of stimulation and 
modifying the dose of gonadotropins as needed. The ovulatory dose of 
hCG (Gonasi®; AMSA SRL, Italy, 10,000 IU) was administered when at 




Table 1 - Characteristics of  patients receiving study treatment. 
Values are expressed as mean ± SD; ns = not significant; p- value 




Table 2 - Ovarian stimulation protocols in the treatment groups. alues 
are expressed as IU ± SD; ns = not significant; *p- value measured P 
& R vs. U 
 
As a routine practice at our Centre, we evaluated cumulus cells apoptosis 
rate as a molecular biomarker for oocyte competence in all patients 
agreeing to donate discarded cumulus cells for research purposes. The 
collection of cumulus cells material was approved by the Local Ethics 
Committee of “Centro di Biologia della Riproduzione”, Palermo, Italy. As 
a medical research involving human subjects, this study was conducted 
according to the Declaration of Helsinki 2008 (Ref.: NCT01872247). The 
quality embryo was evaluated in according to ASEBIR embryo 
assessment criteria: A = top quality; B = good quality (not for elective 
single embryo transfer); C = impaired embryo quality; D = do not 
recommend to transfer (includes all multinucleated embryos) [21].  
Apoptosis in cumulus cells was examined with the use of a terminal 
deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) 
assays [11, 22], as described below, that allowed us to highlight DNA 
fragmentation (last step of apoptosis pathway). The pool of cumulus cells 
was collected after incubating the cumulus-oocyte complex in a solution 
of hyaluronidase (80 IU/mL, Medicult, Jyllinge, Denmark). The released 
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cells were collected in a test tube (Falcon, Franklin Lakes, NJ) containing 
2 ml of basic culture medium (Quinn’s advantage medium with HEPES; 
SAGE IVF, Trumbull, CT) and centrifuged twice at 300 g for 10 min. 
Oocytes were transferred to a culture medium (fertilization medium, 
SAGE IVF) and incubated at 37°C, 5% CO2, until intracytoplasmic sperm 
injection (ICSI) was performed. Cumulus cells were then fixed in 3.7% 
paraformaldehyde for 60 min. After centrifugation at 300 g for 5 min, the 
supernatant was removed and phosphate-buffered saline (PBS)-glycine 
was added (0.1 M glycine in PBS and 0.3 mg/mL bovine serum albumin 
[BSA]). Finally, the cells were mounted on polylysine-coated glass slides 
by cyto-centrifugation [23-25]. 
 
Fluorescent TUNEL assay, or TdT in situ 
 
Cumulus cells were washed for 5 min in PBS and permeated for 10 min 
on ice in 0.1% Triton X100 and 0.1% sodium-citrate in PBS, and then 
washed three times in PBS at room temperature for 5 min each time. 
Cumulus cells were then incubated for 60 min at 37°C in a humidified 
chamber in 50 µL of a mixture containing 5 µl of nucleotide mix, 1 µl of 
TdT enzyme, and 45 µl of equilibration buffer (DeadEnd Fluorometric 
TUNEL System, Promega Italia SRL, Milano, Italy). 
An additional slide was incubated with the same mixture without the TdT 
enzyme (negative control), while another slide was pretreated for 5 min 
with 100 µL of DNase buffer, and then treated for 10 min with a DNase 
buffer solution containing 10 unit/ml of DNase I (positive control). The 
reaction was blocked with SSC for 15 min, then followed by three 5 min-
washes in PBS. Cumulus cells were stained with propidium iodide (1 
µg/ml) for 10 min at room temperature and observed under a fluorescent 
microscope equipped with a x20 0.40 objective. 
Apoptosis rate or DNA fragmentation index (DFI) indicates the percent 
value of apoptotic cells observed; total apoptotic nuclei labelled in green 
(TUNEL assay) / total nuclei labelled in red (Propidium iodide) x 100. 
 
Statistical analysis 
Data were analyzed with the statistical software package SPSS version 17. 
All the analyses presented were assessed using a two-sided significance 
level, α, of 0.05. 
To verify the normal distribution of the population the Kolmogorov – 
Smirnov test was used and the Levene test was performed to analyze the 
homogeneity of variance.  
To compare significant differences between the mean values two tests 
were used, Welch and Brown-Forsythe. Analysis of variance (ANOVA) 
models were used to compare treatment groups, except for the LH 
variables, where a T-test for independent variables was used. 
The η squared was used to calculate the effect size. Non parametric 
analysis was performed with Kruskal-Wallis test. Data are presented as 




The study of apoptosis on discarded cumulus cells performed on 
individual groups with Fluorescent TUNEL assay allowed us to quantify 
the DNA fragmentation index (DFI), expression of apoptosis (Figure 1). 
As can you see the fig.1 shows DNA fragmentation, expressed by green 
fluorescent chromatin for each treatment group (A1, B1, C1), the second 
column (A2, B2, C2) shows the total nuclei labelled in red (Propidium 
iodide) (A2, B2, C2) and the third column shows a merge of green and red 
(A3, B3, C3).  (see in orange the cell with DNA fragmentation).  
Collected data showed a relatively high DNA Fragmentation Index, 
measured as total apoptotic nuclei labelled in green (TUNEL assay) / total 
nuclei labelled in red (Propidium iodide) x 100, in U group. Comparing 
the results obtained with different ovarian stimulation protocols, the DFI 
significantly higher in U group was than in the other two, especially 




Figure 1 - TUNEL assay in situ. A = R Group; B = U Group; C = P 
Group. Green: DNA fragmentation (A1, B1, C1). Red: nucleic acids 
stained with Propidium Iodide (A2, B2, C2). Merge of green and red 




Figure 2 - Apoptosis in cumulus cells: DFI in three treatment group 
 
The respective numbers of collected oocytes, fertilized oocytes and good 
quality embryo (a/b) were significantly higher in either P or R groups than 
in U group (see table 4).  Collected data were related to only embryos of 
category A and B (top and good quality) in according to ASEBIR embryo 
assessment criteria [21]. 
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Furthermore U group patients needed to be treated with higher significant 
amount of FSH (Table 2). At last, group U showed lower but not 
statistically significant implantation and pregnancy rates (Table 4). 
 
 
    
Table 3 - Apoptosis in cumulus cells measured TUNEL assay. HP-
hMG (U Group), r-hFSH (R Group) and r-hFSH/r-hLH (P Group). 
DFI = DNA fragmentation index. Values are expressed as mean ± SD; 
ns = not significant; p- value reported when significant. *(P vs. U and  
U vs. P) 
 
 
Table 4 - Clinical outcome of COS. HP-hMG (U Group), r-hFSH (R 
Group) and r-hFSH/r-hLH (P Group). GV-MI oocytes = germinal 
vescicle and metaphase I oocyte MII oocytes = metaphase II oocyte 
embryo a/b = good quality embryo E2 = 17 beta estradiol. Values are 
expressed as mean ± SD; ns = not significant; p- value reported when 
significant. 
4. Discussion 
In this study we evaluated the effects of different ovarian stimulation 
protocols on oocyte competence and secondly their clinical outcome, in 
patients hyporesponders to FSH stimulation.  Results obtained showed 
high efficacy, in term of either DFI or clinical outcome, of recombinant 
gonadotropins treatments compared to HP-hMG treatment.  
Historically in the treatment of infertility and in ARTs, urinary human 
menopausal gonadotropin (u-hMG), from post-menopausal women, has 
been used to stimulate folliculogenesis. Over the years, technological 
advances have led to the ability to produce recombinant forms of human 
FSH (r-hFSH) and LH (r-hLH).  
These are now available as potential alternatives to u-hMG and may be 
more suitable in those sub populations of patients requiring the addition of 
LH in their stimulation protocols. 
During the follicular phase of the ovarian cycle, growth and follicular 
recruitment are stimulated mainly by FSH while during the late phase of 
follicular growth is supported mainly by the LH. The induction of cell 
differentiation and the support of the final stages of follicle maturation 
depend on the action of LH. To get more mature follicles, and thus 
increase the yield of oocytes from patients for ARTs pharmacological 
strategies rely on the modulation of the administration of exogenous 
gonadotropins with COS protocols tailored. LH supplementation can be 
achieved through the administration of r-hLH or hCG (more than 80% of 
homology with LH). The similarity of action of LH and hCG may depend 
on the fact that both gonadotropins bind the same LH/CG receptor. For 
this reason, hCG has become an alternative source of exogenous LH 
activity during COS for ART cycles. Our results may suggest HP-hMG 
treatment is less effective than r-hFSH/r-hLH treatment. It is conceivable 
that, while interacting with the same receptor, r-LH and hCG may 
differently support follicle maturation and development. These data are 
consistent with our previous results [11], showing that supplementation 
with r-hLH related with the reduction of apoptosis rate in COC and 
production embryos with a higher implantation potential. 
Moreover, both in vitro and clinical studies have recently challenged the 
hypothesis of LH and hCG bioequivalence [26]. Differences were 
observed when the recombinant forms of the two gonadotropins were used 
in vitro to stimulate primary and immortalized granulose cells. For 
example, hCG, was 5-times more potent than LH for cAMP accumulation, 
while maximal LH stimulation was 6-fold faster. Conversely, LH was a 
stronger activator of the ERK1/2 and AKT pathways. Inhibition of 
ERK1/2 enhanced aromatase gene expression mediated by LH. On the 
contrary this effect was not observed in patient treated with hCG, 
suggesting that, downstream LHCG-R, intracellular signaling activation 
may diverge and lead to different targets [27].  
In our model, we could speculate that extractive HCG, contained in HP-
hMG, was not able to reduce apoptosis in cumulus cells due to the high 
dosage exposure of LH/CGR to hCG that down-regulated the receptor. In 
addition, hCG is not acting on the granulose cell with the same pathways 
involved by LH, and is not effective in activating the AKT pathway which 







EUROMEDITERRANEAN BIOMEDICAL JOURNAL 2017,12 (11) 051–056                                                                                                                  55 
 
Our results showed that use of r-hFSH significantly improved the number 
of collected oocytes and at the same time reduced the dose of exogenous 
gonadotropins administration. This result is in line with previous literature 
data [13, 28]. A recently published study demonstrated that the expression 
level of LH/hCG receptor gene was reduced in hMG-treated granulosa 
cells compared with recombinant FSH–treated granulosa cells [29].                       
This could explain why ovarian stimulation with recombinant FSH (with 
or without r-hLH) induces significantly more follicles and more oocytes 
retrieved.  
We further demonstrated that increased pregnancy and implantation rates 
were obtained in patients who were treated with recombinant 
gonadotropins than in patients treated with HP-hMG. These results were 
not statistically significant probably for the limited number of study 
patients. 
Our data seem to confirm the important role of native LH in reducing 
apoptosis in the cumulus cells, probably supporting the actions of a series 
of paracrine factors. Kinase Akt, members of bcl-2 family, KIT-ligand 
and c-KIT receptors, stem cell factor (SCF), members of TGF-beta family 
(activing, factors BMP-4 and BMP-7, GDF9), estrogens, insulin and 
IGFs, epidermal growth factor (EGF), basic fibroblast growth factor 
(bFGF), TGF-α, interleukin 1b (IL-1b), growth hormone (GH) and the 
member of apoptosis inhibitors, surviving could promote survival during 
the growth and differentiation of follicles [27].  
LH could induce the expression and the synthesis of EGF-like growth 
factors such as amphiregulin, epiregulin, and betacellulin and activate the 
EGF receptor pathway in the granulosa cells of preovulatory follicles, 
thereby impacting on ovulation [26, 27, 29, 30].  
Results of this study are in favour of the use of a combination treatment r-
hFSH and r-hLH to stimulate ovarian functions. It is tempting to speculate 
that this strategy may contribute to create a better microenvironment in 
the follicle than that observed in patient treated with HP-hMG. 
Recombinant combination treatment was also able to produce better 
oocyte competence, embryo viability and less FSH administration. A 
larger, prospective, randomized study is needed to confirm the data of this 
observational prospective pilot study. 
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